Login to Your Account



ZymoGenetics Soars 26% on $1.1B HCV Drug Deal with BMS

By Donna Young


Wednesday, January 14, 2009
ZymoGenetics Inc.'s stock leaped 26 percent Tuesday on the news that it signed a deal potentially worth more than $1.1 billion with pharma giant Bristol-Myers Squibb Co. to develop and commercialize the Seattle-based biotech's early-stage hepatitis C drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription